Cardiovascular Prehabilitation in Patients Awaiting Heart Transplantation (PREHAB HTx Study) (PREHAB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02957955|
Recruitment Status : Recruiting
First Posted : November 8, 2016
Last Update Posted : September 24, 2019
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure||Behavioral: High-Intensity Interval Training||Not Applicable|
Heart failure affects more than 6.2 million people living in North America. Approximately 10% of patients with heart failure have advanced heart failure. Heart transplantation is an effective life-saving treatment for patients with advanced heart failure. The cardiovascular rehabilitation programs are integral to heart failure management.
This study is being done to evaluate, in adults with advanced heart failure awaiting heart transplantation, the effects of cardiovascular rehabilitation (including high-intensity interval training, stress management and nutrition workshops) on functional capacity, aerobic power, frailty, quality of life, and mental health.
This study compares pre-transplant cardiovascular rehabilitation with usual pre-transplant care in patients with advanced heart failure awaiting heart transplant.
All participants will be randomized into 2 study groups: Group 1 (rehab), and Group 2 (no rehab). Those randomized to Group 1 will receive usual care, 12 weeks of rehab (exercise training, and attend stress and nutrition course through the Heart Failure Clinic and the Division of Prevention and Rehabilitation at the University of Ottawa Heart Institute). Those randomized to Group 2 will receive regular visits through the Heart Failure Clinic; patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Cardiovascular Prehabilitation in Patients Awaiting Heart Transplantation - Addressing Clinical Needs (PREHAB HTx Study)|
|Actual Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||November 2020|
Group 1. Usual care + High-Intensity Interval Training, Nutritional Workshop, Stress Management Course.
Behavioral: High-Intensity Interval Training
Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
No Intervention: Non interventional
Group 2. Usual care. Patients are encouraged to remain physically active, although they do not participate in a regular structured exercise training program.
- Change in functional capacity [ Time Frame: Baseline to 12 weeks ]Change in in functional capacity from baseline to 12 weeks as measured by six-minute walk test distance. Distance walked will be measured in meters.
- Change in aerobic power [ Time Frame: Baseline to 12 weeks ]Measured using expired VO2 gas samples, measured in L/min, ml/kg/min
- Change in frailty [ Time Frame: Baseline to 12 weeks ]Measured by the Fried criteria. Measured by presence of 3 out of 5 frailty symptoms.
- Change in general quality of life [ Time Frame: Baseline to 12 weeks ]Measured by the Short Form 36 Health Survey Questionnaire (SF-36). The SF-36 consists of 8-scaled scores which are the weighted sums of the questions in their section.
- Change in disease-specific quality of life [ Time Frame: Baseline to 12 weeks ]Measured by the Minnesota Living with Heart Failure Questionnaire (MLHFQ). MLHFQ is a 21-item scale that measures the effects of heart failure on quality of life using a 6-point scale.
- Change in depressive symptoms [ Time Frame: Baseline to 12 weeks ]Measured by the Beck Depression Inventory II (BDI-II). It contains 21-questions, each answer being scored on a scale of 0 to 3.
- Change in anxiety [ Time Frame: Baseline to 12 weeks ]Measured by the Beck Anxiety Inventory (BAI). The BAI is a 21-item validated self-reported measure. A total score is calculated by summing the items; maximum score is 62.
- Change in cognitive function [ Time Frame: Baseline to 12 weeks ]Measured by the Montreal Cognitive Assessment (MOCA). The MOCA is made up of 8 subscales, scores are totaled; maximum score is 30 points.
- Change in response to a specific traumatic event [ Time Frame: Baseline to 12 weeks ]Measured by the Impact of Events Scale- Revised (IES-R). IES-R is 22 items, zero to four scale. Scores above 23 are of concern; scores above 32 indicate a probable diagnosis of PTSD.
- Short term post-heart transplantation outcomes [ Time Frame: One year post-heart transplantation ]Data collected from medical records: length of hospital stay, adverse events (infection, treated rejection, bleeding, and stroke), survival to hospital discharge, and 30 day hospital readmissions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957955
|Contact: Jennifer Reed, Ph.D, R.Kin||6136967392 ext email@example.com|
|Contact: Allyson Thomas, RN||613-696-7000 ext firstname.lastname@example.org|
|University of Ottawa Heart Institute||Recruiting|
|Ottawa, Ontario, Canada, K1Y4W7|
|Contact: Jennifer L Reed, PhD 6136967392 ext 67392 email@example.com|
|University Health Network||Recruiting|
|Toronto, Ontario, Canada|
|Contact: Natalia Nugaeva|
|Principal Investigator:||Jennifer Reed, Ph.D, R.Kin||Ottawa Heart Institute Research Corporation|